Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Valme University Hospital
Sponsor:
Collaborators:
Hospital Universitario Virgen de la Victoria
Hospital Universitario Reina Sofia
Hospital Torrecárdenas
Hospital de la Línea de la Concepción
Hospital Poniente
Virgen de la Macarena University Hospital
Complejo Hospitalario de Especialidades Juan Ramón Jimenez
Information provided by (Responsible Party):
Karin Neukam, Valme University Hospital
ClinicalTrials.gov Identifier:
NCT01908660
First received: June 28, 2013
Last updated: May 28, 2014
Last verified: May 2014
  Purpose

The purpose of this study is to compare the liver toxicity in HIV-infected patients with chronic hepatitis B and/or hepatitis C, who start a new antiretroviral drug regimen, as well as the influence of the degree of pre-existing liver fibrosis on the incidence of liver toxicity.


Condition Intervention
Human Immunodeficiency Virus
Hepatitis B, Chronic
Hepatitis C, Chronic
Drug: antiretroviral drugs

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 1 Year
Official Title: Hepatic Safety of Currently Used Antiretroviral Regimens in HIV-infected Patients With Chronic Hepatitis B and/or Hepatitis C Under Real Life Conditions: The HEPAVIR HEPATIC SAFETY Cohort.

Resource links provided by NLM:


Further study details as provided by Valme University Hospital:

Primary Outcome Measures:
  • Incidence of grade 3 or 4 transaminase elevations [ Time Frame: one year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Incidence of grade 3 or 4 bilirubin elevations [ Time Frame: one year ] [ Designated as safety issue: Yes ]
  • Percentage of patients with undetectable HIV RNA at the end of follow-up [ Time Frame: one year ] [ Designated as safety issue: No ]
  • CD4 cell count at the end of follow-up [ Time Frame: one year ] [ Designated as safety issue: No ]

Estimated Enrollment: 500
Study Start Date: January 2007
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Antiretroviral drugs
Pre-treated or treatment-naive HIV-infected patients with chronic hepatitis B and/or chronic hepatitis C who change an existing antiretroviral regimen or who start a new regimen.
Drug: antiretroviral drugs
zidovudine lamivudine emtricitabine abacavir tenofovir nevirapine efavirenz etravirine rilpivirine lopinavir atazanavir fosamprenavir darunavir raltegravir maraviroc ritonavir

  Hide Detailed Description

Detailed Description:

In the last years, various clinical trials and studies have evaluated the incidence of hepatic toxicity (HT) associated with the commonly used antiretroviral drugs in the HIV/hepatitis C virus (HCV)-infected population. Unfortunately, clinical trials that compared hepatic safety of these antiretrovirals include a low number of coinfected patients (van Leth 2004, Molina 2010, Ortiz 2008, Rockstroh 2012). According to recent cohort studies, rates of grade 3 or 4 transaminase elevations (TE) observed in patients receiving ritonavir-boosted protease inhibitors PI/r as lopinavir (LPV/r), atazanavir (ATV/r), fosamprenavir (FPV/r) and darunavir (DRV/r) are similar to those observed in individuals that receive efavirenz (EFV) or raltegravir (RAL) (Pineda 2008, Palacios 2006, Macías 2011, Neukam 2011). However, this conclusion may not be exact due to methodological problems. In this context, currently available data on severe TE are derived from cohort studies that were conducted in different populations, with distinct methods and/or data that was collected retrospectively.

Little information is available on whether the stage of liver damage influences the incidence of HT caused by antiretroviral drugs. Although two studies found an association between advanced fibrosis and higher rates of TE (Aranzabal 2005, Mira 2006), data obtained by further studies are contradictory (Pineda 2008, Palacios 2006, Macías 2011, Neukam 2011) and there are still open questions. Thus, the number of cirrhotic patients is considerably small in these cohorts, however, cirrhosis represents an important comorbidity in HIV. In these individuals, plasmatic concentrations of antiretroviral drugs could reach toxic levels which would be reflected in TE (Barreiro 2007).

Therefore, studies conducted in the same population and with the same methodology are required in order to obtain precise and reliable information on hepatic safety of all commonly used antiretroviral drugs in the clinical practice. These findings could contribute to a better understanding of differences between antiretrovirals and could therefore improve the individualization of antiretroviral therapy in individuals with chronic hepatitis B and/or C. Therefore, the HEPAVIR group of the Andalusian Society of Infectious Diseases (SAEI) has established a prospective cohort: The HEPAVIR Cohort.

Hypothesis: The incidence of severe TE associated with antiretroviral therapy in the clinical practice in hepatitis B virus and/or hepatitis C virus-coinfected patients could be different according to the administered drug.

Primary objective: To determine the incidence of grade 3 or 4 TE associated with antiretroviral therapy in the clinical practice in patients with viral hepatitis.

Secondary objectives:

  • Identification of factors associated with grade 3 or 4 TE
  • Analysis of the association between TE and pre-existing hepatic damage
  • Evaluate the incidence of serious symptoms, including hepatic decompensations, acute fulminant hepatitis and death due to liver failure, associated with the antiretroviral drug
  • Determination of the incidence of grade 3 or 4 bilirubin elevations associated with the antiretroviral drugs
  • Evaluation of efficacy of the antiretroviral drugs used in the study

Scheduled visits: 0, 4, 12, 24, 36 and 48 weeks.

Definition of grade 3 or 4 laboratory abnormalities/data dictionary: Grade 3 transaminase elevations (TE) are considered when elevations between 5 and 10 times above the upper level of normality (ULN) are presented in patients with normal baseline levels of alanine-aminotransferase (ALT) and aspartate-aminotransferase (AST). Grade 4 TE are defined as ALT or AST values >10 times of the ULN. In patients with elevated baseline ALT or AST levels, 3.5- to 5-fold increase from baseline levels are considered grade 3 TE and >5-fold elevations grade 4 TE, respectively. Grade 4 total bilirubin elevations were defined as increases of total bilirubin ≥5 mg/dl.

Definition of hepatic fibrosis:

  • advanced fibrosis: F3 as determined by liver biopsy or 11 kilopascals as determined by transient elastometry
  • cirrhosis: F4 as determined by liver biopsy or 14.6 kilopascals as determined by transient elastometry

Variables collected within in the cohort:

  • primary outcome variable: AST, ALT
  • epidemiological variable: age, sex
  • variables related to hepatitis C virus-infection: infection route, genotype, grade of hepatic fibrosis and method used for its determination, baseline Child-Pough-Index, previous hepatic decompensations
  • variables related to HIV-infection: Centers for Disease Control and Prevention (CDC) category, HIV viral load, cluster of differentiation 4 (CD4) cell count, previous and new antiretroviral drugs
  • analytical variables: platelets, cholesterol, bilirubin, gamma-glutamyltransferase (GGT), alkaline phosphatase
  • clinical variables: alcohol intake
  • time to TE
  • percentage of patients who discontinued antiviral therapy due to TE

Quality assurance and data checks: Data will be obtained from controlled databases at the participating centers. Databases will be monitored and controlled by queries every six months. Descriptive statistics will be be applied in order to detect transcription errors.

Source data verification: not planned.

All grade 3 or 4 adverse events, as well as all unexpected events, will be reported to the Andalusian Center for Pharmacovigilance (Centro Andaluz de Farmacovigilancia, www.cafv.es).

A sample size of 500 is planned for this study.

Statistical analysis:

The outcome variables of this study will be the development of grade 3 or 4 transaminase elevations (TE) and grade 4 total bilirubin elevations (TBE) during follow-up. Comparative analyses of TE and TBE will be carried out between the different drug groups. Additionally, the relationship between the outcome variable and the following potential predictors will be assessed: age, sex, previous intravenous drug use, alcohol consumption, baseline ALT levels, baseline CD4 cell count, CDC category C, undetectable plasma HIV-RNA, HCV genotype, previous ART, type of drug, as well as significant fibrosis and cirrhosis at initiation of the new ART regimen. Continuous variables will be expressed as median [interquartile range (IQR)] and categorical variables as number [percentage; 95% confidence interval (CI)]. The density of incidence of grade 3-4 TE will be calculated as number of cases per 100 person-years of the follow-up. Continuous variables will be compared using the Student's t-test for normal distribution and the Mann-Whitney U-test otherwise, whereas the categorical variables will be analyzed applying the χ2-test or the Fisher's test, when applicable. The Wilcoxon Signed Rank test and the McNemar test will be applied to compare repeated measurements in continuous and categorical variables, respectively. Those factors that show an association in the univariate analysis with a p<0.2, as well as those with a biologically possible influence, will be entered into a logistic regression model in order to identify independent risk factors for grade 3-4 TE and grade 4 TBE. The adjusted odds ratio (AOR) and the respective 95% CI will be calculated. All p values <0.05 will be considered statistically significant. Data will be analysed using the SPSS statistical software package release 19.0 (SPSS Inc., Chicago, IL, USA) and STATA 9.0 (StataCorp LP, College Station, TX, USA).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients seen at the infectious disease unit of a terciary care center

Criteria

Inclusion Criteria:

  • Older than 18 years
  • HIV-1 infection as confirmed by ELISA and western blot
  • Chronic HCV infection as confirmed by HCV antibodies in plasma, as well as a positive HCV viral load determined by polymerase chain reaction OR chronic hepatitis B infection as confirmed by HBsAg
  • Treatment-naive or pretreated patients who start a new antiretroviral regimen that includes at least one drug that has not been received by the patient before
  • At least one week of exposure to new regimen
  • Liver biopsy or transient elastometry determination within 12 months prior to treatment initiation

Exclusion Criteria:

  • Pregnancy
  • Treatment against hepatitis C virus infection
  • Presence of opportunistic infections, including tuberculosis, neoplasia, autoimmune diseases. Patients receiving primary or secondary chemotherapy against an opportunistic process are not included.
  • Any liver disease of vascular, metabolic, biliary, autoimmune or tumoral origin
  • Patients who are not able to provide written informed consent to participate in the study
  • Lack of scheduled clinical visits including blood analysis throughout study period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01908660

Contacts
Contact: Karin I Neukam, PhD 0034955015871 karin.neukam@gmail.com
Contact: José A Mira-Escarti, MD 0034955015684 miraescarti@yahoo.es

Locations
Spain
Hospital Universitario de Valme Recruiting
Seville, Spain, 41014
Contact: Karin I Neukam, PhD    0034955871    karin.neukam@gmail.com   
Contact: José A Mira-Escarti, MD    0034955015684    miraescarti@yahoo.es   
Principal Investigator: Karin I Neukam, PhD         
Sub-Investigator: José A Mira-Escarti, MD         
Sub-Investigator: Juan A Pineda-Vergara, MD, PhD         
Sub-Investigator: Juan Macías-Sánchez, MD, PhD         
Sponsors and Collaborators
Valme University Hospital
Hospital Universitario Virgen de la Victoria
Hospital Universitario Reina Sofia
Hospital Torrecárdenas
Hospital de la Línea de la Concepción
Hospital Poniente
Virgen de la Macarena University Hospital
Complejo Hospitalario de Especialidades Juan Ramón Jimenez
Investigators
Principal Investigator: Karin I Neukam, PhD Hospital Universitario de Valme
  More Information

Publications:

Responsible Party: Karin Neukam, PhD, Valme University Hospital
ClinicalTrials.gov Identifier: NCT01908660     History of Changes
Other Study ID Numbers: SEG-HEP-2007
Study First Received: June 28, 2013
Last Updated: May 28, 2014
Health Authority: Spain: Agencia Española de Medicamentos y Productos Sanitarios

Keywords provided by Valme University Hospital:
HIV
hepatitis C virus
hepatitis B virus
antiretroviral drugs
nucleos(t)ide reverse transcriptase inhibitors
non-nucleos(t)ide reverse transcriptase inhibitors
protease inhibitors
integrase inhibitors
entry inhibitors
transaminase elevations
alanine aminotransferase
aspartate aminotransferase
bilirubin elevations
hepatic fibrosis

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis, Chronic
Hepatitis C
Immunologic Deficiency Syndromes
Hepatitis B, Chronic
Hepatitis C, Chronic
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immune System Diseases
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Enterovirus Infections
Picornaviridae Infections
Hepadnaviridae Infections
DNA Virus Infections
Flaviviridae Infections
Reverse Transcriptase Inhibitors
Integrase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on July 24, 2014